MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spivak, C. E.
Right arrow Articles by Surratt, C. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spivak, C. E.
Right arrow Articles by Surratt, C. K.

Vol. 52, Issue 6, 983-992, 1997

Naloxone Activation of µ-Opioid Receptors Mutated at a Histidine Residue Lining the Opioid Binding Cavity

Charles E. Spivak, Carol L. Beglan, Brian K. Seidleck, Laura D. Hirshbein, Carrie J. Blaschak, George R. Uhl, and Christopher K. Surratt

Cellular Neurobiology (C.K.S.) and Molecular Neurobiology (C.E.S., C.L.B., B.K.S., L.D.H., C.J.B., G.R.U.) Branches, Intramural Research Program, National Institute on Drug Abuse, Baltimore, Maryland 21224

The µ-opioid receptor is the principal site of action in the brain by which morphine, other opiate drugs of abuse, and endogenous opioid peptides effect analgesia and alter mood. A member of the seven-transmembrane domain (TM) G protein-coupled receptor (GPCR) superfamily, the µ-opioid receptor modulates ion channels and second messenger effectors in an opioid agonist-dependent fashion that is reversible by the classic opiate antagonist naloxone. Mutation of a histidine residue (His297) in TM 6 afforded agonist-like G protein-coupled signal transduction mediated by naloxone and other alkaloid antagonists and enhanced the intrinsic activity of documented alkaloid partial agonists, including buprenorphine. The intrinsic activities of all opioid peptide agonists and antagonists tested were not altered at the His297 mutant receptors. Consistent with a role for the TM 6 histidine in maintaining high affinity binding sites for opioid agonists and antagonists, opioid ligand-dependent protection of this residue from a histidine-specific alkylating agent indicated that the His297 side chain is positioned in or very near the binding cavity. The TM 6 His297 mutants identify a discrete region of the receptor critical for determining whether a specific drug pharmacophore triggers receptor activation. Because many GPCRs possess a similarly positioned TM histidine residue, our findings with the µ-opioid receptor may extend to these receptors and potentially serve as a model for rational design of therapeutic GPCR partial agonists and antagonists.

Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J EndocrinolHome page
A. Leanos-Miranda, A. Ulloa-Aguirre, L. A Cervini, J. A. Janovick, J. Rivier, and P M. Conn
Identification of new gonadotrophin-releasing hormone partial agonists.
J. Endocrinol., June 1, 2006; 189(3): 509 - 517.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. A. Claude-Geppert, J. Liu, J. Solberg, L. J. Erickson-Herbrandson, H. H. Loh, and P.-Y. Law
Antagonist Efficacy in MORS196L Mutant Is Affected by the Interaction between Transmembrane Domains of the Opioid Receptor
J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 216 - 226.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
M. Albrizio, A. C. Guaricci, F. Maritato, R. L. Sciorsci, G. Mari, G. Calamita, G. M. Lacalandra, G. G. Aiudi, R. Minoia, M. E. Dell'Aquila, et al.
Expression and subcellular localization of the {micro}-opioid receptor in equine spermatozoa: evidence for its functional role
Reproduction, January 1, 2005; 129(1): 39 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
W. Wang, M. S. Sonders, O. T. Ukairo, H. Scott, M. K. Kloetzel, and C. K. Surratt
Dissociation of High-Affinity Cocaine Analog Binding and Dopamine Uptake Inhibition at the Dopamine Transporter
Mol. Pharmacol., August 1, 2003; 64(2): 430 - 439.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Pil and J. Tytgat
Serine 329 of the {micro}-Opioid Receptor Interacts Differently with Agonists
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 924 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Chavkin, J. P. McLaughlin, and J. P. Celver
Regulation of Opioid Receptor Function by Chronic Agonist Exposure: Constitutive Activity and Desensitization
Mol. Pharmacol., July 1, 2001; 60(1): 20 - 25.
[Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. B. Deng, W. Guang, and J. B. Wang
Selected Cysteine Residues in Transmembrane Domains of {micro}-Opioid Receptor Are Critical for Effects of Sulfhydryl Reagents
J. Pharmacol. Exp. Ther., April 1, 2000; 293(1): 113 - 120.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
Y.-M. Sun, C. A. Flanagan, N. Illing, T. R. Ott, R. Sellar, B. J. Fromme, J. Hapgood, P. Sharp, S. C. Sealfon, and R. P. Millar
A Chicken Gonadotropin-releasing Hormone Receptor That Confers Agonist Activity to Mammalian Antagonists. IDENTIFICATION OF D-LYS6 IN THE LIGAND AND EXTRACELLULAR LOOP TWO OF THE RECEPTOR AS DETERMINANTS
J. Biol. Chem., March 9, 2001; 276(11): 7754 - 7761.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics